Developing new small molecules to treat pan-coronavirus infections
Advancing the development of a novel class of small molecules for treating pan-coronavirus infections
This study is looking for new small molecules that can help treat infections from coronaviruses, like the one that causes COVID-19, by targeting certain parts of the virus's life cycle, and it's designed for anyone interested in better treatments for these infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11177204 on NIH RePORTER |
What this research studies
This research focuses on creating a new class of small molecules aimed at treating infections caused by various coronaviruses, including SARS-CoV-2. The approach involves targeting specific cellular kinases that play a role in the virus's life cycle and inflammatory response. By optimizing a series of compounds known as RMC-113, the researchers aim to find effective antiviral agents that can reduce viral load without causing toxicity. The study will utilize advanced medicinal chemistry techniques to enhance the efficacy of these compounds.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of or currently infected with coronaviruses, particularly SARS-CoV-2.
Not a fit: Patients with non-coronavirus related viral infections or those who do not have a history of severe respiratory illnesses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective treatments for COVID-19 and other coronavirus infections.
How similar studies have performed: Previous research has shown promise in targeting cellular kinases for antiviral therapies, indicating a potential for success with this novel approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Einav, Shirit — Stanford University
- Study coordinator: Einav, Shirit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.